U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07588945) titled 'daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT' on April 24.
Brief Summary: This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Transplant-Related Disorder
Intervention:
DRUG: Ruxolitinib
1. Model-predicted high-risk patients: will receive standard prophylaxis plus ruxolitinib 5mg twice daily (bid) orally until at least day 60 post-transplantion and will be terminated after day 100. If severe hematological signs occur such as when there...